Biomarker use in the prostate cancer screening pathway: Maps of the evidence
- 1Center for Early Cancer Detection American Cancer Society Atlanta Georgia USA
- 2Research Integrity Oregon Health & Science University Portland Oregon USA
Abstract
Prostate‐specific antigen (PSA)–based screening provides limited information about which individuals may harbor clinically significant prostate cancer (csPCa) and benefit from biopsy; tools such as magnetic resonance imaging (MRI) and biomarkers are being evaluated to improve risk stratification. Clinical utility reflects balancing reducing biopsies with avoiding missed csPCas, and biomarkers have been proposed to inform these decisions. In this study, evidence maps were constructed to characterize the clinical utility of biomarkers in the prostate cancer screening pathway, with or without MRI and other tools. PubMed and the Cochrane Central Register of Controlled Trials were searched from inception to October 2025 for studies evaluating common blood‐, urine‐, and saliva‐based biomarkers in asymptomatic adults after an abnormal PSA. Eligible studies compared biomarker‐based pathways with other strategies and reported clinical utility measures. Screening pathways were classified as “biomarker” or “nonbiomarker,” and findings were categorized by whether study investigators reported greater clinical utility for one pathway, the other, or no difference. Across 68 studies, biomarker‐based pathways were generally reported to reduce biopsies while maintaining csPCa detection compared to nonbiomarker pathways. Results were broadly consistent across biomarkers. Studies generally reported better clinical utility when biomarkers were used concurrently with or after MRI compared to biomarker alone, although few evaluated sequencing. Limited evidence suggests that biomarkers may add value in individuals undergoing repeat biopsy or with equivocal MRI findings, whereas their benefit beyond MRI was less clear in biopsy‐naive populations. Biomarkers improve risk stratification after an elevated PSA, and may enhance decision‐making when used alongside MRI. However, heterogeneity in study populations and evaluated pathways limits interpretation.
Related
- D-DIMER AS A BIOMARKER IN PROSTATE CANCER: A SCOPING REVIEW OF CURRENT EVIDENCE
- Prostate cancer screening beyond opportunistic testing: A Delphi consensus and evidence integration
- Pan-Cancer Analysis Identifies LUC7L2 as a Prognostic Biomarker and Potential Functional Regulator of Prostate Cancer Progression
- DUSP13 promotes prostate cancer progression by regulating the ERK1/2 pathway
- Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
BibTeX
@article{shiau2026biomarker,
title = {{Biomarker use in the prostate cancer screening pathway: Maps of the evidence}},
author = {Rita L. Shiau and Jessica C. Griffin and Clarissa A. B. Troutman and Rose Relevo and Karli K. Kondo},
journal = {Cancer},
year = {2026},
month = nov,
doi = {10.1002/cncr.70627},
url = {https://doi.org/10.1002/cncr.70627},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Biomarker use in the prostate cancer screening pathway: Maps of the evidence
AU - Rita L. Shiau
AU - Jessica C. Griffin
AU - Clarissa A. B. Troutman
AU - Rose Relevo
AU - Karli K. Kondo
PY - 2026
DA - 2026/11/12
JO - Cancer
DO - 10.1002/cncr.70627
UR - https://doi.org/10.1002/cncr.70627
AB - Prostate‐specific antigen (PSA)–based screening provides limited information about which individuals may harbor clinically significant prostate cancer (csPCa) and benefit from biopsy; tools such as magnetic resonance imaging (MRI) and biomarkers are being evaluated to improve risk stratification. Clinical utility reflects balancing reducing biopsies with avoiding missed csPCas, and biomarkers have been proposed to inform these decisions. In this study, evidence maps were constructed to characterize the clinical utility of biomarkers in the prostate cancer screening pathway, with or without MRI and other tools. PubMed and the Cochrane Central Register of Controlled Trials were searched from inception to October 2025 for studies evaluating common blood‐, urine‐, and saliva‐based biomarkers in asymptomatic adults after an abnormal PSA. Eligible studies compared biomarker‐based pathways with other strategies and reported clinical utility measures. Screening pathways were classified as “biomarker” or “nonbiomarker,” and findings were categorized by whether study investigators reported greater clinical utility for one pathway, the other, or no difference. Across 68 studies, biomarker‐based pathways were generally reported to reduce biopsies while maintaining csPCa detection compared to nonbiomarker pathways. Results were broadly consistent across biomarkers. Studies generally reported better clinical utility when biomarkers were used concurrently with or after MRI compared to biomarker alone, although few evaluated sequencing. Limited evidence suggests that biomarkers may add value in individuals undergoing repeat biopsy or with equivocal MRI findings, whereas their benefit beyond MRI was less clear in biopsy‐naive populations. Biomarkers improve risk stratification after an elevated PSA, and may enhance decision‐making when used alongside MRI. However, heterogeneity in study populations and evaluated pathways limits interpretation.
SN - 0008-543X
SN - 1097-0142
ER -